Beacon Topco

Beacon Therapeutics is a clinical-stage biotechnology company specializing in the development of gene therapies for retinal diseases. Established in 2023 through the combination of AGTC's assets and new research from the University of Oxford, the company focuses on treating both rare and common causes of blindness. Its lead candidate, AGTC-501, is currently in Phase 2/3 clinical trials for X-linked retinitis pigmentosa (XLRP). Beacon utilizes a proprietary adeno-associated virus (AAV) platform to deliver functional copies of genes to the retina, aiming to provide durable therapeutic benefits to patients. The company is backed by prominent life science investors including Syncona and Forbion.